05-172
Anti-IGF-I Antibody, clone Sm1.2
clone Sm1.2, Upstate®, from mouse
Sinónimos:
Mechano growth factor, insulin-like growth factor 1, insulin-like growth factor 1 (somatomedin C), somatomedin C
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Productos recomendados
biological source
mouse
Quality Level
antibody form
purified immunoglobulin
clone
Sm1.2, monoclonal
species reactivity
avian, chicken, mouse, rat, human
manufacturer/tradename
Upstate®
technique(s)
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
neutralization: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... IGF1(3479)
General description
Insulin-like growth factor 1 (IGF-1) is a polypeptide protein hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges.
IGF-1 is produced primarily by the liver as an endocrine hormone and targets tissues in a paracrine/autocrine fashion. Production is stimulated by growth hormone and can be retarded by undernutrition, growth hormone insensitivity, lack of growth hormone receptors, or failures of the downstream signaling pathway post GH receptor including SHP2 and STAT5b. Approximately 98% of IGF-1 is always bound to one of 6 binding proteins (IGF-BP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. IGF-1 binds to IGFBP-3 in a 1:1 molar ratio. Its primary action is mediated by binding to specific IGF receptors present on many cell types in many tissues. The signal is transduced by intracellular events. IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and multiplication and a potent inhibitor of programmed cell death.
IGF-1 is produced primarily by the liver as an endocrine hormone and targets tissues in a paracrine/autocrine fashion. Production is stimulated by growth hormone and can be retarded by undernutrition, growth hormone insensitivity, lack of growth hormone receptors, or failures of the downstream signaling pathway post GH receptor including SHP2 and STAT5b. Approximately 98% of IGF-1 is always bound to one of 6 binding proteins (IGF-BP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. IGF-1 binds to IGFBP-3 in a 1:1 molar ratio. Its primary action is mediated by binding to specific IGF receptors present on many cell types in many tissues. The signal is transduced by intracellular events. IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and multiplication and a potent inhibitor of programmed cell death.
Specificity
IGF-I. (Russel, W.E., 1984). 40% cross reactivity to IGF-II. (van Wyk, J.J., 1997).
Possibly chicken. Occasional difficulty neutralizing rat IGF-I due to binding protein interference.
Immunogen
Human insulin-like growth factor I (IGF-I) purified from human plasma. (van Wyk, J.J., 1986).
Application
Anti-IGF-I Antibody, clone Sm1.2 is an antibody against IGF-I for use in IH, IP, NEUT & WB.
Immunoprecipitation:
5 μg of a previous lot immunoprecipitated 100 ng of IGF-I.
Immunohistochemistry:
10 μg/mL of a previous lot was reported by an independent laboratory to detect IFG-I in formalin-fixed, paraffin-embedded skin sections.
(Lui, 1994).
Neutralization:
10-20 μg/mL of a previous lot inhibited the activity of 10 ng/mL of IGF-I as determined by testing with chicken embryo fibroblasts (CEF) using an ATP endpoint assay (ATPLiteTM-M, Packard Instruments).
5 μg of a previous lot immunoprecipitated 100 ng of IGF-I.
Immunohistochemistry:
10 μg/mL of a previous lot was reported by an independent laboratory to detect IFG-I in formalin-fixed, paraffin-embedded skin sections.
(Lui, 1994).
Neutralization:
10-20 μg/mL of a previous lot inhibited the activity of 10 ng/mL of IGF-I as determined by testing with chicken embryo fibroblasts (CEF) using an ATP endpoint assay (ATPLiteTM-M, Packard Instruments).
Research Category
Signaling
Signaling
Research Sub Category
Insulin/Energy Signaling
Insulin/Energy Signaling
Quality
Evaluated on IGF-I (Catalog # 01-208) under non-reducing conditions.
Western Blot Analysis:
0.5-2 μg/mL of this antibody detected 100 ng of IGF-I (Catalog # 01-208) under non-reducing conditions.
Western Blot Analysis:
0.5-2 μg/mL of this antibody detected 100 ng of IGF-I (Catalog # 01-208) under non-reducing conditions.
Target description
17 kDa, migrates to ~7 kDa
Physical form
Format: Purified
Protein G Purified
Purified mouse IgG1κ lyophilized powder, lyophilized from 105 μL of 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.1 mM EDTA.
Storage and Stability
Stable for 1 year at -20ºC from date of receipt.
Analysis Note
Control
MCF-7 cell extracts
MCF-7 cell extracts
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Peter Zahradka et al.
Endocrinology, 145(6), 2978-2987 (2004-02-21)
Angiotensin II (AngII) activates phosphatidylinositol 3-kinase (PI3-kinase), a known effector of receptor tyrosine kinases. Treatment of smooth muscle cells with AngII has also been shown to promote phosphorylation of various tyrosine kinase receptors. We therefore investigated the relationship between AngII
Cryogenic spinal cord injury induces astrocytic gene expression of insulin-like growth factor I and insulin-like growth factor binding protein 2 during myelin regeneration
Yao, D. L., et al
Journal of Neuroscience Research, 40, 647-659 (1995)
Growth factors and stromal matrix proteins associated with mammographic densities.
Y P Guo, L J Martin, W Hanna, D Banerjee, N Miller, E Fishell, R Khokha, N F Boyd
Cancer Epidemiology, Biomarkers & Prevention null
Expression of insulin-like growth factor I (IGF-I) in nevi and melanomas.
M G Fleming, S F Howe, L H Graf
The American Journal of Dermatopathology null
PTH ameliorates acidosis-induced adverse effects in skeletal growth centers: the PTH-IGF-I axis.
Green, J; Goldberg, R; Maor, G
Kidney International null
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico